Medtronic Infuse Adverse-Event Reporting Gaps Spotlighted
This article was originally published in The Gray Sheet
Executive Summary
The Minneapolis-based Star Tribune says Medtronic failed to report more than 750 adverse events uncovered during a 2006-2008 chart review of Infuse patients. But the company struck back, saying the newspaper’s version omits key facts.
You may also be interested in...
No Advantage For Medtronic’s InFuse Versus Bone Graft In Spine Fusion
The long-awaited independent analysis of clinical data on Medtronic’s InFuse recombinant human bone morphogenetic protein-2 (rhBMP-2) found no advantages to using it as a substitute for traditional bone grafts in spinal fusion surgery, while also revealing that the risks of rhBMP-2 may be greater than has been previously reported.
Korean Bioclusters Offer Tax, Other Incentives To Attract Global Firms, Talent
South Korea has formulated new detailed policy measures to support the formation of major bioclusters, which will offer tax and other incentives in a bid to lure foreign firms and talent.
CDC Panel Backs Pfizer’s Maternal RSV Vaccine But Leaves Room For AstraZeneca/Sanofi’s Beyfortus
Abrysvo is recommended for use in pregnant people 32-36 weeks gestation if administered from September to January. For infants whose mothers were not vaccinated in this window, nirsevimab is recommended for prevention of respiratory syncytial virus infection.